CytomX Therapeutics, Inc.

Historical 13F Holders

Symbol
CTMX
CUSIP
23284F105
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 23284F105 since 12/18/2024, largest first.

Filer % of Class Filed
FMR LLC 13G/A
14.6% 2/5/2026
Event 12/31/2025
Kynam Capital Management, LP 13G/A
10.0% 8/14/2026
Event 6/30/2026
BlackRock, Inc. 13G 7.6% 7/27/2026
Event 6/30/2026
Longitude Capital Partners V, LLC 13G/A
7.0% 5/15/2026
Event 3/31/2026
Bank of America Corp /DE/ 13G/A 5.4% 10/28/2026
Event 9/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (11)
Perceptive Advisors LLC 13G/A
4.6% 5/15/2026
Event 3/31/2026
Venrock Healthcare Capital Partners III, L.P. 13G/A
4.6% 5/15/2026
Event 3/31/2026
State Street Corp 13G 4.1% 11/10/2026
Event 9/30/2026
Point72 Asset Management, L.P. 13G/A
3.6% 8/14/2026
Event 6/30/2026
Biotechnology Value Fund L P 13G/A
3.5% 7/9/2025
Event 7/3/2025
OrbiMed Advisors LLC 13G/A 2.1% 2/17/2026
Event 12/31/2025
Seven Fleet Capital Management LP 13G/A
0.5% 5/15/2026
Event 3/31/2026
Seven Fleet Partners LP 13G
0.2% 5/20/2025
Event 5/13/2025
Janus Henderson Group PLC 13G/A 0% 2/14/2025
Event 12/31/2024
Tang Capital Management LLC 13G/A
0% 2/17/2026
Event 12/31/2025
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 196 216 M $588M
2026 Q2 179 213 M $799M
2026 Q1 181 193 M $908M
2025 Q4 123 144 M $614M
2025 Q3 105 137 M $439M
2025 Q2 85 133 M $303M
2025 Q1 67 45.3 M $28.8M
2024 Q4 71 46.7 M $48.1M
2024 Q3 71 51.2 M $60.4M
2024 Q2 75 50.7 M $61.9M
2024 Q1 89 44.6 M $97.1M
2023 Q4 69 32.6 M $50.6M
2023 Q3 63 32.4 M $41.8M
2023 Q2 68 34.1 M $58.7M
2023 Q1 77 35.6 M $53.8M
2022 Q4 83 36.2 M $57.8M
2022 Q3 85 36.3 M $52.6M
2022 Q2 100 45.6 M $83.4M
2022 Q1 120 53.7 M $143M
2021 Q4 111 54.5 M $237M
2021 Q3 116 54.0 M $275M
2021 Q2 124 56.7 M $359M
2021 Q1 128 54.6 M $422M
2020 Q4 129 38.0 M $249M
2020 Q3 131 36.8 M $245M
2020 Q2 136 37.8 M $315M
2020 Q1 119 36.1 M $277M
2019 Q4 121 36.0 M $299M
2019 Q3 115 35.8 M $264M
2019 Q2 110 35.7 M $400M
2019 Q1 115 37.1 M $399M
2018 Q4 114 37.8 M $570M
2018 Q3 126 37.9 M $700M
2018 Q2 144 32.5 M $741M
2018 Q1 143 29.7 M $843M
2017 Q4 120 30.1 M $637M
2017 Q3 97 24.2 M $441M
2017 Q2 90 22.1 M $343M
2017 Q1 87 19.2 M $332M
2016 Q4 68 16.9 M $185M
2016 Q3 62 19.7 M $309M
2016 Q2 60 18.8 M $193M
2016 Q1 49 17.7 M $228M
2015 Q4 48 17.4 M $360M